Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities
Article in Cancer Science (May 2024)
The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.
Emerging data on immune checkpoint inhibitors in the neoadjuvant and adjuvant setting for patients with hepatocellular carcinoma
Article in Hepatoma Research (April 2024)
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial
Article in Nature Communications (April 2024)